Glenn Prestwich and Lab

Glenn Prestwich

Presidential Professor of Medicinal Chemistry

 

CONTACT

Phone: 801.585.7396

Email: gprestwich@pharm.utah.edu

Positions:

  • Presidential Professor, and Director, Center for Therapeutic Biomaterials

  • Special Presidential Assistant for Faculty Entrepreneurism

  • Department of Medicinal Chemistry, The University of Utah

Education

  • Postdoctoral Fellow 1974-1977 Cornell University

  • Ph.D. 1974 Stanford University

  • B.S. 1970 California Institute of Technology

Research Interests

colored vials prestwich lab

Research Projects in the Prestwich Research Group

A recent presentations on the application of clinically-targeted hyaluronic acid derivatives in 3-D cell culture, bioprinting, cell therapy, xenograft models, and anti-inflammatory drugs can be viewed on the BioTime website at www.biotimeinc.com. An overview of the anti-inflammatory glycosaminoglycan projects can be found on the GlycoMira website at www.glycomira.com.

The three main research areas for the Prestwich lab are: (i) new reagents for phosphoinositide and lysophospholipid signaling in cell biology and cancer treatment, (ii) biomaterials for cell therapy, wound repair, cartilage repair, tissue engineering, scar-free healing, and xenograft models, and (iii) sulfated glycosaminoglycan analogues as inflammation modulators for clinical use.

Biography

Dr. Glenn D. Prestwich is Presidential Professor of Medicinal Chemistry and Special Presidential Assistant for Faculty Entrepreneurism, and directed two Utah Centers of Excellence: the Center for Cell Signaling (1997-2002) and the Center for Therapeutic Biomaterials (2004 – 2008). His passion for translational research and scholarship led to his appointment as director of the Entrepreneurial Faculty Scholars program at the U of Utah (2008 – current). He was elected as a Fellow of the National Academy of Inventors (2014 - ) and a Fellow of the American Institute for Medical and Biological Engineering (2005 - ).

 

He has launched over nine small life science companies in the last 20 years: Clear Solutions Biotech (1994-2001); Echelon Biosciences, Inc. (CSO, 1997-2003); Sentrx Surgical, Inc. (CSO, 2003-2004); Carbylan BioSurgery, Inc. (Palo Alto, CA)(2004-current); Sentrx Animal Care, Inc. (Salt Lake City)(2005-current); Glycosan BioSystems, Inc. (Salt Lake City) (CSO, 2005-2011); GlycoMira Therapeutics, Inc. (CSO, Salt Lake City) (2008 - current); Metallosensors, Inc. (CEO, 2011 – 2014): Deuteria Agrochemicals LLC (2013 – current); and Deuteria Biomaterials LLC (2013 – current). He is currently a Scientific Advisor for Echelon-Frontier Scientific, University Medical Pharmaceutics, Elastin Specialities, AshaVision, Jade Therapeutics, American MedChem, Organonovo, Modern Meadow, and BioTime.

He received the Utah Governor’s Medal for Science and Technology for 2006, was awarded the 1998 Paul Dawson Biotechnology Award and the 2008 Volwiler Research Award of the American Association of Colleges of Pharmacy. In 2010, he received the University of Utah Distinguished Scholarly and Creative Research Award, as well as the 2010 Rooster Prize of the International Society for Hyaluronan Science for outstanding contributions to hyaluronan-derived products. During his 37 years as a faculty member, he has published over 650 technical papers, patents, and book chapters, and has trained over 125 postgraduate scientists. In 2011, he was invited to serve as a member of the editorial advisory board for Science Translational Medicine. His university research programs included (i) new reagents for lipid signaling in cell biology and cancer treatment, (ii) biomaterials for wound repair, cartilage repair, tissue engineering, scar-free healing, and toxicology and xenograft models, and (iii) sulfated glycosaminoglycan analogues as inflammation modulators for clinical use.

Glenn’s outside interests include: singing first tenor in the Utah Symphony Chorus, using his commercial pilot license to fly non-emergency medical patients for AngelFlight West, and serving on the board of directors of the Orcas Island Chamber Music Festival and the Salt Lake City NOVA Chamber Music Series.

COP Dr. Glenn Prestwich speaker

Publications

    GAG ANTI-INFLAMMATORIES

    Research Publications – Anti-inflammatory Glycosaminoglycans:

    1. N. V. Rao, B. Argyle, X. Xu, P. R. Reynolds, J. M. Walenga, M. Prechel, G. D. Prestwich, R. B. MacArthur, B.  B. Walters, J. R. Hoidal, and T. P. Kennedy, “Low Anticoagulant Heparin Targets Multiple Sites of Inflammation, Suppresses Heparin-Induced Thrombocytopenia and Inhibits Interaction of RAGE with its Ligands,” Am. J. Physiol. Cell Physiol., 299, C97-110. (2010) PMID 20375277
    2. J. Zhang, X. Xu, N. V. Rao, B. Argyle, L. McCoard, W. J. Rusho, T. P. Kennedy, G. D. Prestwich, and G. Krueger, “Novel Sulfated Polysaccharides Disrupt RAGE Ligation and Inhibit Cutaneous Inflammation in a Mouse Model of Rosacea”, PLOS One 6 (2), e16658 (2011)
    3. S. Oottamasathien W. Jia, L. McCoard, S. Slack, J. Zhang, A. Skardal, A., T. P. Kennedy, R. Dull, G. D. Prestwich, “A Murine Model for Inflammatory Bladder Disease: Cathelicidin Peptide-Induced Bladder Inflammation and Treatment with Sulfated Polysaccharides,” J. Urol., 186, 1684-1692 (2011).
    4. S. Oottamasathien, W. Jia, L. McC. Roundy, J. Zhang, X. Ye,, A. C. Hill, J. Savage, W. Y. Lee, A. M Hannon, S. Milner, and G. D. Prestwich, “Physiologic relevance of LL-37 induced bladder inflammation and mast cells,” J. Urology, 190, 1596-1602 (2013).
    5. L. McCoard Roundy, W. Jia, J. Zhang, X. Ye, G. D. Prestwich, S. Oottamasathien, LL-37 induced cystitis and the recept for advanced glycation endproduct (RAGE) pathway, Adv. Biosci. Biotech., 4, 1-8 (2013).
    6. W. Y. Lee, J. R. Savage, J. Zhang, W. Jia, S. Oottamasathien, and G. D. Prestwich, Prevention of anti-microbial peptide LL-37 induced ATP release in the urinary bladder by a modified glycosaminoglycan, PLoS ONE, 8(10) e77854 (2013).
    7. V. Swarup, T. Hsiao, J. Zhang, G. Prestwich, K. Balagurunathan, and V. Hlady, “Exploiting differential surface display of chondroitin sulfate variants for directing neuronal growth,” J. Am. Chem. Soc., 135, 13488-13494 (2013).
    8. G. D. Prestwich, “The evolution of a culture of impact in academia: faculty as mentors for student entrepreneurs,” Science Translational Medicine, 5, 169ed2 (2013).

     

    Book Chapters

    1. N. V. Rao, G. D. Prestwich, J. R. Hoidal, and T. P. Kennedy, ÔøΩLow Anti-Coagulant Heparins in the Treatment of Metastasis,ÔøΩ Melanoma, open access book chapter, ISBN:978-953-307-293-7. March, 2011.

     

    Patents and Pending or Published Patent Applications

    1. Glenn D. Prestwich, Siam Oottamasathien, Wanjian Jia, and Lindsi McCoard,  ÔøΩMethods for Treating or Preventing Urological InflammationÔøΩ, U. S. Continuation-in-Part Patent application filed March, 2011
    2. Glenn D. Prestwich, Jianxing Zhang, N. V. Rao, X. Xu, and Thomas Kennedy, ÔøΩAlkylated Semi-synthetic Glycosaminoglycan Ethers, and Methods of Making and of Use Thereof,ÔøΩ U. S. Patent 7,855,187 (December 21, 2010).
    3. Glenn D. Prestwich and Thomas P. Kennedy, ÔøΩMethods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycan ethers,ÔøΩ US Provisional Patent filed January 26, 2010. PCT filed January 24, 2011.
    4. Glenn D. Prestwich and Thomas P. Kennedy, ÔøΩApplications of Partially Sulfated Hyaluronans,ÔøΩ U.S. Provisional Patent application filed June 8, 2010. PCT filed June 8, 2011.
    5. Glenn D. Prestwich,  Jianxing Zhang. N. Rao, X. Xu, and Thomas Kennedy, ÔøΩAlkylated Semi-synthetic Glycosaminoglycan Ethers, and Methods of Making and of Use Thereof,ÔøΩ PCT and full filing April 3, 2009.
    LIPID SIGNALING

    Research Publications – Lipid Signaling:

    1. A.L. Khandoga, Y. Fujiwara, P. Goyal, D. Pandey, R. Tsukahara, A. Bolen, H. Guo, N. Wilke, J. Liu, W. J. Valentine, G. G. Durgam, D. D. Miller, G. Jiang, G. D. Prestwich, G. Tigyi, W. Seiss, “Lysophosphatidic Acid-induced Platelet Shape Change Revealed through LPA (1-5) Receptorselective Probes and Albumin,” Platelets, 19, 415-427 (2008).
    2. J. Chevallier, Z. Chamoun, G. Jiang, G. D. Prestwich, N. Sakai, S. Matile, R. G. Parton, J. Gruenberg, “Lysobisphosphatidic Acid Controls Endosomal Cholesterol Levels.” J. Biol. Chem., 283, 27871-27880 (2008).
    3. H. Zhang, X. Xu, J. Gajewiak, R. Tsukarara, J. Liu, J. Fells, D. Perygin, A. Parrill, G. Tigyi, G.D. Prestwich, “Dual Activity Lysophosphatidic Acid Receptor Pan Antagonist - Lysophospholipase D Inhibitor Suppresses Breast Cancer Cell Migration and Invasion in vitro and causes Tumor Regression in vivo,” Cancer Res., 69, 5441-5449 (2009).
    4. H. Zhang, J. Thompson, G. D. Prestwich, “A Scalable Synthesis of the IP7 Isomer, 5-PPIns(1,2,3,4,6) P5,” Org. Lett., 11, 1551-1554 (2009).
    5. B. Morrison, E. Lamarre, J. A. Bauer, R. Haney, J. Drazba, G. D. Prestwich, D. J. Linner, “Gene Deletion of Inositol Hexakisphosphate Kinase 2 Predisposes to Aerodigestive Tract Carcinoma,” Oncogene, 28, 2383-2392 (2009).
    6. X. Xu, G. Yang, H. Zhang, G. D. Prestwich, “Evaluating Dual Activity LPA Receptor Pan Antagonist/Autotaxin Inhibitors as Anti-Cancer Agents in vivo Using Engineered Human Tumors,” Prostaglandins other Lipid Mediat., 89, 140-146 (2009).
    7. H. Zhang, J. He, T.G. Kutateladze, T. Sakai, T. Sasaki, N. Markadieu, C. Erneux, G. D. Prestwich, “5-Stabilized Phosphatidylinositol 3,4,5-Trisphosphate Analogues Bind Grp1 PH and Inhibit Neutrophil Migration,” ChemBioChem, 11, 388-395 (2010).
    8. M. D. Best, H. Zhang, and G. D. Prestwich, “Inositol Polyphosphates, Diphosphoinositol Polyphosphates and Phosphatidylinositol Polyphosphate Lipids: Structure, Synthesis, and Development of Probes for Studying Biological Activity,” Natural Products Reviews, 27, 1403-1430 (2010).
    9. N. Oikonomou, M-A. Mouratis, A. Tzouvelekis, C. Valavanis, G. Vilaras, A. Karameris, G. D. Prestwich, G. Jiang, D. Bouros and V.Aidinis, “Pulmonary autotaxin contributes to the pathogenesis of pulmonary fibrosis, Amer. J. Resp. Crit. Care Med., 47, 566-574 (2012). G. Yang, H. Zhang, and G. D. Prestwich, Tissue-Engineered “Metastases”: Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist, J. Cancer Res. Updates, 1, 69-77 (2012).
    10. G. Jiang, D. Madan, G. D. Prestwich, “Aromatic Phosphonate Inhibitors of the Lysophospholipase D Activity of Autotaxin,” Bioorg. Med. Chem. Lett., 21,5098-5101 (2011). M. Record, S. Amara, C. Subra, G. Jiang, G. D. Prestwich, F. Ferrato, I. Douchet, and F. Carriere, “Bis(monoacylglycero)phosphate interfacial properties and lipolysis by the pancreatic lipase-related protein 2 (PLRP2), an enzyme present in THP-1 human monocytes,” Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1811, 419-430 (2011).
    11. J. He, J. Gajewiak, J. Scott, D. Gong, M. Best, G. D. Prestwich, R. Stahelin, T. Kutateladze, “Metabolically stabilized derivatives of phosphatidylinositol 4-phosphate: synthesis and applications,” Chem. Biol., 18, 1312-1319 (2011).
    12. G. Jiang, A. Inoue, J. Aoki, and G. D. Prestwich, “Phosphorothioate analogues of sn-2 radyl lysophosphatidic acid (LPA) as metabolically stabilized agonists for LPA receptors”, Bioorg Med. Chem. Lett. 23, 1865-1869 (2013).
    13. I. Nikitopoulou, E. Kaffe, I. Sevastou, I. Sirioti, M. Samiotaki, D. Madan, G. D. Prestwich, and V. Aidinis, Metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis, PLoS ONE, 8(7): e70941 (2013).
    14. G.Y. Park, Y. G Lee, E. Berdyshev, S Nyenjhuis, J. Du, P. Fu, I. A Gorshkova, Y. Li, S. Chung, M Karpurapu, J. Deng, R. Rajan, L. Xiao, H. A. Jaffe, S. J. Corbridge, E. A. B. Kelly, N. N. Jarjour, J. Chun, G. D. Prestwich, V, Aidinis, A. J. Morris, S. S. Smyth, S. J. Acerman, V. Natarajan, J. W. Christman, “Autaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation,”Am. J. Resp. Critical Care Med., in press (2013).
    15. D. Madan, C. G. Ferguson, W. Y. Lee, G. D. Prestwich, and C. A. Testa, Non-invasive imaging of autotaxin-expressing tumors using an enzyme-activated near-infrared fluorogenic substrate, PLoS ONE, 8(11): e79065 (2013).
    16. G. D. Prestwich, “The evolution of a culture of impact in academia: faculty as mentors for student entrepreneurs,” Science Translational Medicine, 5, 169ed2 (2013).
    REGENERATIVE MEDICINE

    Reviews and Research Publications – Regenerative Medicine:

    REVIEWS

    1. G. D. Prestwich, “Evaluating Drug Toxicity and Efficacy in Three Dimensions: Using Synthetic Extracellular Matrices in Drug Discovery,” Acc. Chem. Res., 41, 139-148 (2008). PMID 17655274
    2. G. D. Prestwich, “Clinical Biomaterials Derived from Hyaluronic Acid for Use in Cell and Molecule Delivery in Regenerative Medicine,” J. Controlled Release, 155, 193-199 (2011). J. Burdick, G. D. Prestwich, “Hyaluronic Acid Hydrogels for Biomedical Applications”, Advanced Materials 23, H41-H56 (2011)
    3. G. D. Prestwich, S. Bhatia, C. K. Breuer, S. Dahl, C. Mason, R. McFarland, C. Mason, D. J. McQuillan, J. Sackner-Bernstein, J. Schox, W. E. Tente, and A. Trounson, “Insider Views: What is the greatest regulatory challenge in the translation of biomaterials to the clinic?” Science Translational Medicine, 4, 160cm14 (2012).
    4. G. D. Prestwich, I. Erickson, T. I. Zarembinski, M. West, and W. P. Tew. “The Translational Imperative: Making Cell Therapy Simple and Effective,” Acta Biomaterialia, 8, 4200-4207 (2012).

    5. K. Cheng, A. Blusztajn, D. Shen, T-S. Li, B. Sun, G. Galang, T. Zarembinski, G. D. Prestwich, E. Marban, R. Ruckdeschel Smith, and L. Marban, “Enhanced Engraftment and Therapeutic Benefit of Human Cardiosphere-derived Cells Delivered in an In Situ Polymerizable Hydrogel”, Biomaterials 33, 5317-24 (2012)

    RESEARCH PUBLICATIONS

    1. L. Hosack, M. A. Firpo, J. A. Scott, G. D. Prestwich, R. A. Peattie, “Microvascular Maturity Elicited in Tissue Treated with Cytokine-loaded Hyaluronan-based Hydrogels,” Biomaterials, 29, 2336-2347 (2008). PMC2387277
    2. Y. Liu, A. Skardal, X. Z. Shu, and G. D. Prestwich, “Prevention of Peritendinous Adhesions Following Flexor Tendon Injury with Carbylan™-SX, a Semisynthetic Glycosaminoglycan Hydrogel,” J. Orthopedic Res., 26, 562-569 (2008). PMID 17985390
    3. A. K. Ekapurta, G. D. Prestwich, S. Cool, and D. W. Hutmacher, “Combining Electrospun Scaffolds with Electrosprayed Hydrogels leads to Three Dimensional Cellularization of Hybrid Constructs,” Biomacromolecules, 9, 2097-2103 (2008). PMID 18646822
    4. J. Zhang, A. Skardal, G. D. Prestwich, “Engineered Extracellular Matrices with Cleavable
      Crosslinkers for Cell Expansion and Easy Cell Recovery,” Biomaterials, 29, 4521-4531 (2008).
      PMC2651085
    5. J. Zhao, N. Zhang, J. A. Scott, G. D. Prestwich, and X. Wen, “Recruitment of Endogenous Stem Cells for Tissue Repair,” Macromolec. Biosci., 8, 836-842 (2008). PMID 18528846
    6. S. L. Thibeault, S. A. Klemuk, M. E. Smith, G. D. Prestwich, “In Vivo Comparison of Biomimetic Approaches for Tissue Regeneration of the Scarred Vocal Fold,” Tissue Eng.,15, 1481-1487, (2009). PMC2792100
    7. G. D. Prestwich, “Clinical Biomaterials for Scar-Free Healing and Localized Delivery of Cells and Growth Factors,” Advances in Wound Care, 1, 394-399 (2010).
    8. G. Yang, L. Espandar, N. Mamalis, G. D. Prestwich, “Accelerated Repair of Corneal Epithelial Abrasion and Alkali Burn Injuries in Rabbits with a Crosslinked Hyaluronan Derivative,” Vet. Ophthalmol., 13, 144-150 (2010).
    9. R. Elia, P. W. Fuegy, A. VanDelden, M. A. Firpo, G. D. Prestwich, and R. A. Peattie, “Stimulation of in vivo angiogenesis by in situ crosslinked, dual growth factor-loaded, glycosaminoglycan hydrogels,” Biomaterials, 31, 4630-4638 (2010). PMC2871388
    10. A. Skardal, S. Sarker, A. Crabbé, C. A. Nickerson, G. D. Prestwich, “The Generation of 3D Tissue Models based on Hyaluronan Hydrogel-Coated Microcarriers within a Rotating Wall Vessel Bioreactor,” Biomaterials, 31, 8426-8435 (2010).
    11. A. Skardal, J. Zhang, L. McCoard, S. Oottamasathien, G. D. Prestwich, “Dynamically Crosslinked Gold Nanoparticle – Hyaluronan Hydrogels,” Adv. Mater., 22, 4736-4740 (2010). A. Skardal, J. Zhang, L. McCoard, X. Xu, S. Oottamasathien, G. D. Prestwich, “Photocrosslinkable hyaluronan-gelatin hydrogels for two-step bioprinting,” Tissue Eng. Part A, 16, 2675-2685 (2010).
    12. G. Yang, B. Mann, G. D. Prestwich, “Thiolated carboxymethyl hyaluronic acid-based
      biomaterials enhance wound healing in rats, dogs, and horses,” ISRN Veterinary Science, 2011,
      ID 851593, 7 pp (2011).
    13. O. A. Lozoya, E. Wauthier, R. Turner, C. Barbier, G. D. Prestwich, F. Guilak, R.Superfine, S. R.
      Lubkin, L. M. Reid, “Mechanical stiffness of the microenvironment regulates hepatic stem/progenitors in experimental models of the stem cell niche of the human liver”, Biomaterials, 32, 7389-7402 (2011).
    14. A. K. Ekaputra, G. D. Prestwich, S. Cool, and D. W. Hutmacher, “Three-dimensional vascularization of growth factor-releasing hybrid scaffold of poly(e-caprolactone)/collagen fibers and hyaluronic acid hydrogel”, Biomaterials, 32, 8108-8117 (2011).
    15. A. Chopra, V. Lin, A. McCollough, S. Atzet, G. D. Prestwich, A. S. Wechsler, M. E. Murray, S. A. Oake, J. Y. Kresh, P. A. Janmey, “Reprogramming Cardiomyoctye Mechanosensing by Crosstalk Between Integrins and Hyaluronic Acid Receptors,” J. Biomechanics 45, 824-831 (2012).
    16. R. Elia, D. R. Newhide, P. D. Pedevillano, G. R. Reiss, M. A. Firpo, E. W. Hsu, D. L. Kaplan, G. D. Prestwch, and R. A. Peattie, “Silk-Hyaluronate-Based Composite Hydrogels: a Novel, Securable Vehicle for Drug Delivery,” J. Biomater. Applic., 27, 749-762 (2011).
    17. R. Bartlett, G. D. Prestwich, and S. L. Thibeault, Therapeutic potential of gel-based injectables for vocal fold regeneration, Biomedical Materials, 7, 024103 IOP Publishing (2012).
    18. G. Bhakta, B.Rai, Z. X. H. Lim, J. H. Hui, G. Stein, A. J. van Wijnen, V. Nurcombe, G. D. Prestwich, and S. M Cool, Ph.D., Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2, Biomaterials, 33, 6113-6122 (2012).
    19. A. Astashkina, B. K. Mann, G. D. Prestwich, and D. W. Grainger, “A 3-D organoid kidneyculture model engineered for high throughput nephrotoxicity assays,” Biomaterials, 33, 4700-4711 (2012).
    20. A. Astashkina, B. K. Mann, G. D. Prestwich, and D. W. Grainger, “Comparing predictive drug nephrotoxicity in kidney 3-D primary organoid culture and immortalized cell lines,” Biomaterials, 33, 4712-4721(2012).
    21. G.D. Prestwich, I. Erickson, T.I. Zarembinski, M. West, and W.P. Tew, “The Translational Imperative: Making Cell Therapy Simple and Effective,” Acta Biomaterialia, 8, 4200-4207 (2012).
    22. G. Bhakta, B.Rai, Z. X. H. Lim, J. H. Hui, G. Stein, A. J. van Wijnen, V. Nurcombe, G. D. Prestwich, and S. M Cool, Ph.D., Hyaluronic acid-based hydrogels functionalized with heparin support controlled release of bioactive BMP-2, Biomaterials, 33, 6113-6122 (2012).
    23. K. Cheng, A. Blusztajn, D. Shen, T-S. Li, B. Sun, G. Galang, T. Zarembinski, G. D. Prestwich, E. Marban, R. Ruckdeschel Smith, and L. Marban, “Enhanced Engraftment and Therapeutic Benefit of Human Cardiosphere-derived Cells Delivered in an In Situ Polymerizable Hydrogel”, Biomaterials 33, 5317-5324 (2012).
    24. A. H. Park, D. Hoyt, D. Britt, S. Chase, K. Tansavatdi, L. Hunter, L. McGill, X. Sheng, A. Skardal, and G. D. Prestwich, “Crosslinked hydrogel and polyester resorbable ventilation tubes in a chinchilla model,” The Laryngoscope, 123, 1043-1048 (2013).
    25. R. Turner, E. Wauthier, O. Lozoya, R. McClelland, J. E. Bowsher, C. Barbier, D. Gerber, G. D. Prestwich, E. Hsu, D. A Gerber and L. M. Reid, Successful Transplantation of Human Hepatic Stem Cells and with Restricted Localization to Liver Using Hyaluronan Grafts, Hepatology, 57, 775-785 (2013)G. D. Prestwich, “Delivery, retention, and engraftment of progenitor cells in cell therapy,” Biomatter 3, 1-2 (2013).
    26. G. Bhakta, Z. X. H. Lim, B. Rai, T. Lin, J. H. Hui, G. D. Prestwich, A. J. van Wijnen, V. Nurcombe, S. M. Cool, The influence of collagen and hyaluronan matrices on the delivery and bioactivity of bone morphogenetic protein-2 and ectopic bone formation, Acta Biomaterialia, 9, 9098-9106 (2013).
    27. G. D. Prestwich, “The evolution of a culture of impact in academia: faculty as mentors for student entrepreneurs,” Science Translational Medicine, 5, 169ed2 (2013).
    28. V. Swarup, T. Hsiao, J. Zhang, G. Prestwich, K. Balagurunathan, and V. Hlady, “Exploiting differential surface display of chondroitin sulfate variants for directing neuronal growth,” J. Am. Chem. Soc., 135, 13488-13494 (2013).
    29. A. Chopra, M. E. Murray, D. Raz-Ben Aroush, M. Mendez, R. Halleluyan, D. Restle, P. A. Galie, F. Byfield, R. Bucki, C. Marcinkiewicz, G. D. Prestwich, T. I. Zarembinski, C. S. Chen, E. Puré, J. Y. Kresh, and P. A. Janmey, “Augmentation of integrin-mediated mechanotransduction by hyaluronic acid,” Biomaterials, 35, 71-82 (2014).

     

     

    Selected patents for Prestwich lab inventions that are used in commercial products

    Patents licensed to Anika Therapeutics, with products in clinical use

    1. J.-w. Kuo, D.A. Swann, and G.D. Prestwich, “Water-Insoluble Derivatives of Hyaluronic Acid and Their Methods of Preparation and Use,” U.S. Patent No. 5,356,883 (October 18, 1994).
    2. J.-w. Kuo, D.A. Swann, and G.D. Prestwich, “Water-Insoluble Derivatives of Hyaluronic Acid and  Their Methods of Preparation and Use,” U.S. Patent No.  5,502,081 (March 26, 1996) (Continuation in Part).
    3. J.-w. Kuo, D.A. Swann, and G.D. Prestwich, “Water-Insoluble Derivatives of Hyaluronic Acid and Their Methods of Preparation and Use,” U.S. Patent No. 6,013,679  (January 11, 2000).
    4. J.-w. Kuo, D.A. Swann, and G.D. Prestwich, “Method for Treating Wounds Using Modified Hyaluronic Acid Crosslinked with Biscarbodiimide,”  U.S. Patent No. 6,096,727 (August 1, 2000).
    5.  J.-w. Kuo, D.A. Swann, and G.D. Prestwich, "Water-Insoluble Derivatives of Hyaluronic Acid Crosslinked with a Biscarbodiimide," U.S. Patent No. 6,537,979 (March 25, 2003).

    Patent licensed to Collagenex and used to monitor ReoPro patients

    1. B.S. Coller and G.D. Prestwich, “Peptidase‑Resistant Thrombin Receptor Peptide Ligand,” U.S. Patent No. 5,455,228 (October 3, 1995).

    Patents forming the basis for regenerative medicine and wound healing products originally developed by Sentrx Surgical (Salt Lake, 2003-2005) Carbylan BioSurgery (Palo Alto, 2005-current) , Glycosan Biosystems (Salt Lake, 2006- 2011; now BioTime, Inc, 2011 - current), and Sentrx Animal Care (Salt Lake, 2006 – current).

    1. T. Pouyani and G.D. Prestwich, “Functionalized Derivatives of Hyaluronic Acid,” U.S. Patent No. 5,616,568 (April, 1, 1997).
    2. T. Pouyani and G.D. Prestwich, “Method for Making Functionalized Derivatives of Hyaluronic Acid,” U.S. Patent No. 5,652,347 (July 29, 1997).
    3. D.M. Marecak and G.D. Prestwich, “Functionalized Derivatives of Hyaluronic Acid,” U.S. Patent No. 5,874,417 (February 23, 1999).
    4. G.D. Prestwich, X.Z. Shu, Y. Luo, K. R. Kirker, and Y. Liu, “Crosslinked Compounds and Methods of Making and Using Thereof,” U.S. Patent 7,928,069 B2 (April 19, 2011).
    5. G.D. Prestwich, K.R. Kirker, S.D. Gray, X.Z. Shu, H. Li, and Y. Liu, “Anti-adhesion Composites and Methods of Use Thereof,” U.S. Patent 8,324,184 (December 4, 2012).
    6. X.Z. Shu, Y. Liu, and G.D. Prestwich, “Modified Macromolecules and Methods of Making and Using Thereof,” U.S. Patent 7,981,871 (July 19, 2011).

    Issued Patents for drug discovery by Echelon Biosciences

    1. C.G. Ferguson and G.D. Prestwich, “Compounds and Methods of Use Thereof for Assaying Lysophospholipase D Activity,” US Patent 7,459,285 (December 2, 2008.)
    2. C.G. Ferguson and G.D. Prestwich, “Compounds and Methods of Use Thereof for Assaying Lysophospholipase D Activity,” Canadian Patent 2,509,099.
    3. C.G. Ferguson, G.D. Prestwich, and D. Madan, “Compounds and Methods of Use Thereof for Assaying Lysophospholipase D Activity, Continuation-in-Part. U. S. Patent 8,512,971 (August 20, 2013).

    Issued Patents for anti-inflammatory compounds for GlycoMira Therapeutics (www.glycomira.com)

    1. Glenn D. Prestwich, Jianxing Zhang, N. V. Rao, X. Xu, and Thomas Kennedy, “Alkylated Semi-synthetic Glycosaminoglycan Ethers, and Methods of Making and of Use Thereof,” U. S. Patent 7,855,187 (December 21, 2010).
    2. Glenn D. Prestwich, Jianxing Zhang, N. V. Rao, and Thomas Kennedy, “Alkylated Semi-synthetic Glycosaminoglycan Ethers, and Methods of Making and of Use Thereof,” U. S. Patent 8,329,673 (December 11, 2012).
    3. Glenn D. Prestwich, Siam Oottamasathien, Wanjian Jia, and Lindsi McCoard,  “Methods for Treating or Preventing Urological Inflammation”, U. S. Patent 8,343,942 (January 1, 2013).
    4. Glenn D. Prestwich, Jianxing Zhang , N. Rao, X. Xu, and Thomas Kennedy, “Alkylated Semi-synthetic Glycosaminoglycan Ethers, and Methods of Making and of Use Thereof,” U. S. Patent 8,399,430 (March 19, 2013).